Peripheral vasodilatation in the treatment of hypertension. Prazosin compared with hydralazine in patients not responding to beta-receptor blockade

Acta Med Scand Suppl. 1982:665:121-4. doi: 10.1111/j.0954-6820.1982.tb00420.x.

Abstract

Prazosin was compared with hydralazine in 39 patients (mean age 49 years), who were already on beta-blockade for arterial hypertension. They all had a resting DBP greater than 100 mm Hg on propranolol 80 mg b i d. They were randomly allocated to prazosin or hydralazine treatment. Blood pressure was measured after 4, 8 and 12 weeks. We noted a significant fall in blood pressure in both groups, in most cases to normotensive levels. Side-effects and other variables of interest are discussed. Together with beta blockade, i e propranolol, both prazosin and hydralazine give good blood-pressure control and no important differences could be found.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Clinical Trials as Topic
  • Double-Blind Method
  • Drug Resistance
  • Drug Therapy, Combination
  • Female
  • Humans
  • Hydralazine / adverse effects
  • Hydralazine / therapeutic use*
  • Hypertension / drug therapy*
  • Male
  • Middle Aged
  • Prazosin / adverse effects
  • Prazosin / therapeutic use*
  • Propranolol / therapeutic use
  • Quinazolines / therapeutic use*
  • Random Allocation
  • Vasodilator Agents / therapeutic use*

Substances

  • Quinazolines
  • Vasodilator Agents
  • Hydralazine
  • Propranolol
  • Prazosin